An Extensively Humanized Mouse Model to Predict Pathways of Drug Disposition and Drug/Drug Interactions, and to Facilitate Design of Clinical Trials
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Species differences in drug metabolism and disposition can confound the extrapolation of in vivo PK data to man and also profoundly compromise drug efficacy studies owing to differences in pharmacokinetics, in metabolites produced (which are often pharmacologically active), and in differential activation of the transcription factors constitutive androstane receptor (CAR) and pregnane X receptor (PXR), which regulate the expression of such enzymes as P450s and drug transporters. These differences have gained additional importance as a consequence of the use of genetically modified mouse models for drug-efficacy testing and also patient-derived xenografts to predict individual patient responses to anticancer drugs. A number of humanized mouse models for cytochrome P450s, CAR, and PXR have been reported. However, the utility of these models has been compromised by the redundancy in P450 reactions across gene families, whereby the remaining murine P450s can metabolize the compounds being tested. To remove this confounding factor and create a mouse model that more closely reflects human pathways of drug disposition, we substituted 33 murine P450s from the major gene families involved in drug disposition, together with Car and Pxr, for human CAR, PXR, CYP1A1, CYP1A2, CYP2C9, CYP2D6, CYP3A4, and CYP3A7. We also created a mouse line in which 34 P450s were deleted from the mouse genome. Using model compounds and anticancer drugs, we demonstrated how these mouse lines can be applied to predict drug-drug interactions in patients and discuss here their potential application in the more informed design of clinical trials and the personalized treatment of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · cited 1×
“…so in the treatment of cancer, where the numerous possible drug combinations involving targeted antitumor agents [most of which are P450 substrates and as shown here also PXR agonists (Zanger and Schwab, 2013)] are being tested to increase efficacy and delay the onset of drug resistance.”
Cross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246 · cited 3×
“For osimertinib the half-life is 3.5 hours inWTmice, 20 hours in 8HUMmice, and 55 hours in patients (Cross et al., 2014).”
InfluentialGenetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502 · cited 1×
“Therefore, an urgent need exists to develop better in vivo models more predictive of human drug response (Kersten et al., 2017).”
BackgroundThe State of Innovation in Drug Development
Kola, I. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100479 · Cited by 276 · cited 1×
“Data obtained during preclinical development often fail their extrapolation to the clinic; this is a major reason for the high rate of attrition in drug development (Kola and Landis, 2004; Kola, 2008).”
BackgroundHenderson, C. J., Otto, D. M. E., Carrie, D., Magnuson, M. A., McLaren, A. W., Rosewell, I., & Wolf, C. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212087200 · Cited by 258 · cited 2×
“S-acenocoumarol metabolism inmicrosomes fromwild-type, Cyp2cKO, Cyp2c/2d/3a KO, or hepatic P450 reductase–null (Henderson et al., 2003) mice was practically indistinguishable from that in the no cofactor control, whereas S-acenocoumarol was rapidly metabolized in liver microsomes from CYP2C9 humanized mice (Fig.”
BackgroundSelf-citation
Cited by
Walter, J., Armet, A. M., Finlay, B. B., & Shanahan, F. (2020) · Cell · doi:10.1016/j.cell.2019.12.025 · Cited by 596
Cross-species analysis of hepatic cytochrome P450 and transport protein expression
Hammer, H., Schmidt, F., Marx-Stoelting, P., Pötz, O., & Braeuning, A. (2021) · Archives of Toxicology · doi:10.1007/s00204-020-02939-4 · Cited by 104
Säll, C., Alifrangis, L., Dahl, K., Friedrichsen, M. H., Nygård, S. B., & Kristensen, K. (2022) · Drug Metabolism and Disposition · doi:10.1124/dmd.122.000865 · Cited by 17
“These limitations have, however, been resolved in a humanized mouse model (8HUM) where 34 murine CYPs have been deleted and replaced with major human drug metabolising CYP enzymes, together with relevant transcription factors CAR and PXR (Henderson et al., 2019).”
BackgroundInfluential
Metadata
- Authors
- Henderson, C. J., Kapelyukh, Y., Scheer, N., Rode, A., McLaren, A. W., MacLeod, A. K., Lin, D., Wright, J., Stanley, L. A., & Wolf, C. R.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 47
- Issue
- 6
- Pages
- 601-615
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2938949182
- Cited by
- 44
- References
- 5
- FWCI
- 5.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.